Cargando…
Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
BACKGROUND: Azvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19. However, the impact of LDH levels in COVID-19 patients receiving Azvudine treatment r...
Autores principales: | Mao, Manyun, Dian, Yating, Sun, Yuming, Chen, Wangqing, Zhu, Wu, Deng, Guangtong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619747/ https://www.ncbi.nlm.nih.gov/pubmed/37920449 http://dx.doi.org/10.3389/fcimb.2023.1237277 |
Ejemplares similares
-
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023) -
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023) -
The Structural Basis of Babesia orientalis Lactate Dehydrogenase
por: Yu, Long, et al.
Publicado: (2022) -
Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
por: Sun, Yuming, et al.
Publicado: (2023) -
Bacterial Interference With Lactate Dehydrogenase Assay Leads to an Underestimation of Cytotoxicity
por: Van den Bossche, Sara, et al.
Publicado: (2020)